Dr. Ramalingam on Pemetrexed and Bevacizumab as Maintenance Therapy for Advanced NSCLC

Video

Cancer Network spoke with Suresh S. Ramalingam, MD, of Emory University, about pemetrexed, bevacizumab, or both for advanced non-squamous NSCLC.

Cancer Network spoke with Suresh S. Ramalingam, MD, professor of hematology/oncology and the deputy director of Winship Cancer Institute, Emory University, about the results of the ECOG-ACRIN 5508 trial (abstract 9002). The study focused on pemetrexed, bevacizumab, or a combination of both as maintenance therapy for advanced non-squamous NSCLC, and the findings were presented at ASCO 2019.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
In a CancerNetwork® YouTube video, Cornelia Tischmacher, a mother of twins from Germany, outlined her receipt of double lung transplantation.
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
Related Content